| 44.84 1.31 (3.01%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 52.47  |
1-year : | 61.29 |
| Resists | First : | 44.93 |
Second : | 52.47 |
| Pivot price | 37.48 |
|||
| Supports | First : | 36.48 |
Second : | 31.26 |
| MAs | MA(5) : | 41.43 |
MA(20) : | 36.62 |
| MA(100) : | 34.7 |
MA(250) : | 31.66 |
|
| MACD | MACD : | 1.9 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 96.5 |
D(3) : | 92 |
| RSI | RSI(14): 83.9 |
|||
| 52-week | High : | 44.93 | Low : | 23.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ COLL ] has closed above the upper band by 5.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 176.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 44.96 - 45.09 | 45.09 - 45.24 |
| Low: | 43.22 - 43.38 | 43.38 - 43.56 |
| Close: | 44.55 - 44.8 | 44.8 - 45.08 |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Mon, 10 Nov 2025
Collegium Pharmaceutical: Another Solid Quarter - Seeking Alpha
Sat, 08 Nov 2025
A Look at Collegium Pharmaceutical’s (COLL) Valuation After Upbeat Q3 Results and Raised Guidance - Yahoo Finance
Sat, 08 Nov 2025
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 28% Jump Shows Its Popularity With Investors - simplywall.st
Sat, 08 Nov 2025
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2025 Earnings Call Transcript - Insider Monkey
Fri, 07 Nov 2025
HC Wainwright & Co. Maintains Collegium Pharmaceutical (COLL) Buy Recommendation - Nasdaq
Fri, 07 Nov 2025
Collegium Pharmaceutical: Q3 Earnings Snapshot - ctinsider.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 32 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 116.2 (%) |
| Shares Short | 5,230 (K) |
| Shares Short P.Month | 4,450 (K) |
| EPS | 1.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.36 |
| Profit Margin | 5.1 % |
| Operating Margin | 20 % |
| Return on Assets (ttm) | 7.7 % |
| Return on Equity (ttm) | 16.1 % |
| Qtrly Rev. Growth | 29.3 % |
| Gross Profit (p.s.) | 19.64 |
| Sales Per Share | 22.44 |
| EBITDA (p.s.) | 11.92 |
| Qtrly Earnings Growth | -34 % |
| Operating Cash Flow | 203 (M) |
| Levered Free Cash Flow | 336 (M) |
| PE Ratio | 42.3 |
| PEG Ratio | 0 |
| Price to Book value | 6.09 |
| Price to Sales | 1.99 |
| Price to Cash Flow | 6.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|